Initial Treatment for Long Segment Transverse Myelitis with Dysautonomia

Immediate Management Steps

The American College of Neurology recommends immediately initiating high-dose intravenous methylprednisolone 1 gram daily for 3-5 days combined with IVIG 2 g/kg over 5 days for severe longitudinally extensive transverse myelitis (LETM) with dysautonomia 1
Permanently discontinue any immune checkpoint inhibitors or other potential causative medications immediately upon presentation, as these can trigger immune-mediated myelitis, according to the Journal of Clinical Oncology 1, 2

Administer IV methylprednisolone 1 gram daily for 3-5 days as pulse dosing, as recommended by the Journal of Clinical Oncology 1, 2
Simultaneously initiate IVIG 2 g/kg divided over 5 days (0.4 g/kg/day), as recommended by the Journal of Clinical Oncology 1, 3
The combination therapy approach is specifically recommended when severe dysautonomia is present, requiring aggressive treatment, according to the Journal of Neurology, Neurosurgery and Psychiatry 4

Perform frequent neurologic examinations and pulmonary function monitoring to assess for respiratory compromise, as recommended by the Journal of Clinical Oncology 3
Monitor closely for autonomic dysfunction manifestations, including blood pressure instability, temperature dysregulation, and cardiac arrhythmias, according to the Journal of Clinical Oncology 3
Evaluate and manage urinary retention and constipation, which are common autonomic complications, as recommended by the Journal of Clinical Oncology 1, 3

Consider plasma exchange (5-10 sessions every other day) if no clinical improvement occurs within 7-10 days of combined corticosteroid and IVIG therapy, as recommended by the Journal of Neurology, Neurosurgery and Psychiatry 1, 4
Initiate PLEX earlier (within 3 days) if symptoms worsen or progress despite initial therapy, according to the Journal of Clinical Oncology 2

Obtain MRI of the entire spine with and without contrast using thin axial cuts to confirm T2-weighted hyperintense lesions extending ≥3 vertebral segments, as recommended by the Journal of Clinical Oncology 1
Include cervical and thoracic spine imaging to assess full extent of involvement, according to the Journal of Clinical Oncology 2
Perform lumbar puncture for CSF analysis including cell count, protein, glucose, oligoclonal bands, IgG index, viral PCRs, and onconeural antibodies, as recommended by the Journal of Neurology, Neurosurgery and Psychiatry 1, 4

Avoid medications that can worsen autonomic dysfunction, including beta-blockers, IV magnesium, and certain antibiotics, as recommended by the Journal of Clinical Oncology 3
Monitor orthostatic vital signs regularly to assess severity of autonomic involvement, according to the Journal of Clinical Oncology 5

Factors predicting poor outcomes include extensive spinal cord lesions on MRI, severe muscle weakness or sphincter dysfunction at presentation, and delayed treatment initiation, as recommended by the Journal of Neurology, Neurosurgery and Psychiatry 1

Do not delay treatment while awaiting antibody results - initiate immunotherapy based on clinical and MRI findings, as recommended by the Journal of Clinical Oncology 1
Do not use corticosteroids alone in severe presentations with dysautonomia - combination therapy is indicated, according to the Journal of Neurology, Neurosurgery and Psychiatry 1, 4
Do not overlook concurrent myasthenia gravis or myositis, which can occur with immune checkpoint inhibitor-related cases and requires specific management, as recommended by the Journal of Clinical Oncology 3